title: [Multidisciplinary approach as a model for detection and monitoring of psychiatric morbidity in patients treated with interferon and ribavirin].
abstract: OBJECTIVE
  We aimed to describe the incidence of psychiatric disorders in a cohort of HCV infected patients treated with interferon and ribavirin, and their impact on treatment adherence and viral response rate (SVR).
  
  
  METHODS
  Retrospective analysis of a cohort of HCV patients visited at an outpatient pharmacy service (OPS). We included all adult patients monoinfected with HCV who had initiated treatment in 2010. Monitoring of psychiatric disorders was assessed at weeks 0, 4, 12, 24, 48, and 72 through the self-administered questionnaires Hospital Anxiety and Depression Scale (HADS) and General Health Questionnaire (Goldberg).Adherence to treatment was assessed by counting of drug dispensations and patient reporting and drug exposure with the 80/80/80 rule. Virologic response was determined by the physician according to standard definitions.
  
  
  RESULTS
  Among 76 included patients, 19 (25%) had a preexisting psychiatric disorder. The incidence of confirmed psychiatric disorders was 33% (n=25),with a peak of abnormal results in the tests by week 12. Overall, 43% of patients achieved an SVR. There were not significant differences between strict adherence and SVR in patients with or without medically confirmed disorders(96.0% vs 96,8%; p = NS) and SVR (39% vs 52%; p = NS], respectively.
  
  
  CONCLUSIONS
  Psychiatric side effects had no effect on adherence to treatment nor on attainment of SVR. Multidisciplinary monitoring provided during the treatment of hepatitis C can contribute to early detection and management of psychiatric disorders and to improve integrated patient care.
authors.affiliation: Servicio de Farmacia. Hospital de Sabadell. Institut Universitari Parc Taulí. Universitat Autònoma de Barcelona.. marta.cabre.serres@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Cabré Serres
authors.affiliation: Servicio de Farmacia. Hospital de Sabadell. Institut Universitari Parc Taulí. Universitat Autònoma de Barcelona..
authors.forename: N
authors.initials: N
authors.lastname: Rudi Sola
authors.affiliation: Unidad de Farmacología Clínica. Hospital de Sabadell. Institut Universitari Parc Taulí. Universitat Autònoma de Barcelona..
authors.forename: C
authors.initials: C
authors.lastname: Pontes García
authors.affiliation: Servicio de Enfermedades Digestivas. Hospital de Sabadell. Institut Universitari Parc Taulí. Universitat Autònoma de Barcelona..
authors.forename: M
authors.initials: M
authors.lastname: Vergara Gómez
authors.affiliation: Servicio de Psiquiatría. Salut Mental Parc Taulí. Institut Universitari Parc Taulí. Universitat Autònoma de Barcelona. España..
authors.forename: I
authors.initials: I
authors.lastname: Parra Uribe
authors.affiliation: Servicio de Farmacia. Hospital de Sabadell. Institut Universitari Parc Taulí. Universitat Autònoma de Barcelona..
authors.forename: M Q
authors.initials: MQ
authors.lastname: Gorgas Torner
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D015897:Comorbidity; D016903:Drug Monitoring / Q000379:methods*; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000523:psychology*; D006801:Humans; D007372:Interferons / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced* / Q000453:epidemiology; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons